LY900014 + insulin glargine

A combination regimen of **LY900014 (insulin lispro-aabc)**, marketed as Lyumjev, and **insulin glargine** is used as a basal-bolus insulin therapy in diabetes mellitus. LY900014 is a rapid-acting insulin analog (insulin lispro-aabc) designed for mealtime glucose control, with a faster onset and offset compared to standard insulin lispro. It is formulated with treprostinil and citrate to accelerate absorption. Insulin glargine is a long-acting basal insulin analog, providing steady insulin levels for up to 24 hours. When used in combination, this regimen mimics physiological insulin secretion—LY900014 manages postprandial spikes while insulin glargine addresses fasting and between-meal glycemic control. The primary indication is for **glycemic control in adults with type 1 and type 2 diabetes mellitus**[1][2].

Other names

insulin lispro-aabc + insulin glargine